GPER expression is known to be significantly lower in ovarian cancer tissue compared to benign and low-malignant ovarian tumors, indicating its potential role as a biomarker for disease progression and a potential molecular target for ovarian cancer [5]. This evidence concerns the gene GPER1 and ovarian carcinoma.